Rodent experiments have emphasized a role of central fatty acid (FA) species, such as oleic acid, in regulating peripheral glucose and energy metabolism. Thus, we hypothesized that central FAs are related to peripheral glucose regulation and energy expenditure in humans. To test this we measured FA species profiles in cerebrospinal fluid (CSF) and plasma of 32 individuals who stayed in our clinical inpatient unit for 6 days. Body composition was measured by dual energy X-ray absorptiometry and glucose regulation by an oral glucose test (OGTT) followed by measurements of 24 hour (24EE) and sleep energy expenditure (SLEEP) as well as respiratory quotient (RQ) in a respiratory chamber. CSF was obtained via lumbar punctures; FA concentrations were measured by liquid chromatography/mass spectrometry. As expected, FA concentrations were higher in plasma compared to CSF. Individuals with high concentrations of CSF very-long-chain saturated FAs had lower rates of SLEEP. In the plasma moderate associations of these FAs with higher 24EE were observed. Moreover, CSF monounsaturated long-chain FA (palmitoleic and oleic acid) concentrations were associated with lower RQs and lower glucose area under the curve during the OGTT. Thus, FAs in the CSF strongly correlated with peripheral metabolic traits. These physiological parameters were most specific to long-chain monounsaturated (C16:1, C18:1) and very-long-chain saturated (C24:0, C26:0) FAs. Conclusions: Together with previous animal experiments these initial cross-sectional human data indicate that central FA species are linked to peripheral glucose and energy homeostasis.
References
[1]
Das UN (2006) Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 1: 420–439.
[2]
Stefan N, Kantartzis K, Celebi N, Staiger H, Machann J, et al. (2010) Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care 33: 405–407.
[3]
Warensjo E, Riserus U, Vessby B (2005) Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 48: 1999–2005.
[4]
Warensjo E, Ohrvall M, Vessby B (2006) Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Nutr Metab Cardiovasc Dis 16: 128–136.
[5]
Kien CL, Bunn JY, Ugrasbul F (2005) Increasing dietary palmitic acid decreases fat oxidation and daily energy expenditure. Am J Clin Nutr 82: 320–326.
[6]
Ohrvall M, Sundlof G, Vessby B (1996) Gamma, but not alpha, tocopherol levels in serum are reduced in coronary heart disease patients. J Intern Med 239: 111–117.
[7]
Pan DA, Lillioja S, Milner MR, Kriketos AD, Baur LA, et al. (1995) Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J Clin Invest 96: 2802–2808.
[8]
Kawashima A, Sugawara S, Okita M, Akahane T, Fukui K, et al. (2009) Plasma fatty acid composition, estimated desaturase activities, and intakes of energy and nutrient in Japanese men with abdominal obesity or metabolic syndrome. J Nutr Sci Vitaminol (Tokyo) 55: 400–406.
[9]
van den Berg SA, Guigas B, Bijland S, Ouwens M, Voshol PJ, et al. (2010) High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity. Nutr Metab (Lond) 7: 24.
[10]
Warensjo E, Riserus U, Gustafsson IB, Mohsen R, Cederholm T, et al. (2008) Effects of saturated and unsaturated fatty acids on estimated desaturase activities during a controlled dietary intervention. Nutr Metab Cardiovasc Dis 18: 683–690.
[11]
Zhou YE, Egeland GM, Meltzer SJ, Kubow S (2009) The association of desaturase 9 and plasma fatty acid composition with insulin resistance-associated factors in female adolescents. Metabolism 58: 158–166.
[12]
Jakobsson A, Westerberg R, Jacobsson A (2006) Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog Lipid Res 45: 237–249.
[13]
Kitazawa H, Miyamoto Y, Shimamura K, Nagumo A, Tokita S (2009) Development of a high-density assay for long-chain fatty acyl-CoA elongases. Lipids 44: 765–773.
[14]
Zadravec D, Brolinson A, Fisher RM, Carneheim C, Csikasz RI, et al. (2010) Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. FASEB J 24: 4366–4377.
[15]
Lam TK, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J, et al. (2005) Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 11: 320–327.
[16]
Ross RA, Rossetti L, Lam TK, Schwartz GJ (2010) Differential effects of hypothalamic long-chain fatty acid infusions on suppression of hepatic glucose production. Am J Physiol Endocrinol Metab 299: E633–E639.
[17]
Haywood SC, Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ (2009) Central but not systemic lipid infusion augments the counterregulatory response to hypoglycemia. Am J Physiol Endocrinol Metab 297: E50–E56.
[18]
Obici S, Feng Z, Morgan K, Stein D, Karkanias G, et al. (2002) Central administration of oleic acid inhibits glucose production and food intake. Diabetes 51: 271–275.
[19]
Schwinkendorf DR, Tsatsos NG, Gosnell BA, Mashek DG (2011) Effects of central administration of distinct fatty acids on hypothalamic neuropeptide expression and energy metabolism. Int J Obes (Lond) 35: 336–344.
[20]
Cha SH, Hu Z, Chohnan S, Lane MD (2005) Inhibition of hypothalamic fatty acid synthase triggers rapid activation of fatty acid oxidation in skeletal muscle. Proc Natl Acad Sci U S A 102: 14557–14562.
[21]
Cha SH, Rodgers JT, Puigserver P, Chohnan S, Lane MD (2006) Hypothalamic malonyl-CoA triggers mitochondrial biogenesis and oxidative gene expression in skeletal muscle: Role of PGC-1alpha. Proc Natl Acad Sci U S A 103: 15410–15415.
[22]
Kumar MV, Shimokawa T, Nagy TR, Lane MD (2002) Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice. Proc Natl Acad Sci U S A 99: 1921–1925.
[23]
Thupari JN, Landree LE, Ronnett GV, Kuhajda FP (2002) C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A 99: 9498–9502.
[24]
Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C (1986) Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J Clin Invest 78: 1568–1578.
[25]
Cadas H, di TE, Piomelli D (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 17: 1226–1242.
[26]
Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, et al. (2007) Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 282: 1518–1528.
[27]
Giuffrida A, Rodriguez de FF, Piomelli D (2000) Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 280: 87–93.
[28]
Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, et al. (2008) The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8: 281–288.
[29]
Weyer C, Snitker S, Rising R, Bogardus C, Ravussin E (1999) Determinants of energy expenditure and fuel utilization in man: effects of body composition, age, sex, ethnicity and glucose tolerance in 916 subjects. Int J Obes Relat Metab Disord 23: 715–722.
[30]
Jumpertz R, Guijarro A, Pratley RE, Piomelli D, Krakoff J (2011) Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J Clin Endocrinol Metab 96: 787–791.
[31]
Smedman AE, Gustafsson IB, Berglund LG, Vessby BO (1999) Pentadecanoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am J Clin Nutr 69: 22–29.
[32]
Cunnane SC, Schneider JA, Tanqney C, Tremblay-Mercier J, Fortier M, et al. (2012) Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 29: 691–697.
[33]
Mitchell RW, Hatch GM (2011) Fatty acid transport into the brain: of fatty acid fables and lipid tails. Prostaglandins Leukot Essent Fatty Acids 85: 293–302.
[34]
Edmond J (2001) Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J Mol Neurosci 16: 181–193.
[35]
Dhopeshwarkar GA, Subramanian C, McConnell DH, Mead JF (1972) Fatty acid transport into the brain. Biochim Biophys Acta 255: 572–579.
[36]
Esposito G, Giovacchini G, Liow JS, Bhattacharjee AK, Greenstein D, et al. (2008) Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET. J Nucl Med 49: 1414–1421.
[37]
Chen CT, Green JT, Orr SK, Bazinet RP (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 79: 85–91.
[38]
Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, et al. (1998) Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72–76.
[39]
Mizuno TM, Makimura H, Silverstein J, Roberts JL, Lopingco T, et al. (1999) Fasting regulates hypothalamic neuropeptide Y, agouti-related peptide, and proopiomelanocortin in diabetic mice independent of changes in leptin or insulin. Endocrinology 140: 4551–4557.
[40]
Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131–141.
[41]
Ste ML, Miura GI, Marsh DJ, Yagaloff K, Palmiter RD (2000) A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci U S A 97: 12339–12344.
[42]
Krakoff J, Ma L, Kobes S, Knowler WC, Hanson RL, et al. (2008) Lower metabolic rate in individuals heterozygous for either a frameshift or a functional missense MC4R variant. Diabetes 57: 3267–3272.
[43]
Kien CL, Bunn JY (2007) Effects of palmitate and oleate on the respiratory quotient during acute feeding. Obesity (Silver Spring) 15: 1640–1642.
[44]
Cederholm J, Wibell L (1990) Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10: 167–175.
[45]
Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, et al. (2010) Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med 153: 790–799.
[46]
Yang ZH, Miyahara H, Hatanaka A (2011) Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. Lipids Health Dis 10: 120.
[47]
Borkman M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, et al. (1993) The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 328: 238–244.
